Alcon Acquired by Novartis
On December 15, 2010, Novartis (NYSE: NVS) agreed to acquire the remaining shares of Alcon, Inc. (NYSE: ACL) it doesn't currently own for $168 per share.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
The merger consideration will be comprised of a combination of Novartis shares and, if necessary, a cash contingent value amount to result in a total value of $168 per share.
Upon completion of the merger, Alcon will become the second largest division within Novartis. CIBA VISION and select Novartis ophthalmic medicines will be integrated into Alcon, forming an organization with more than $8.7 billion in sales covering over 70 percent of the eye care segment.
View Older Stories View More Recent Stories
-
Alcon Celebrates World Sight Day 2020 and Continues Commitment to Improving Worldwide Access to Eye Care
-
Alcon to Showcase Innovations at #Academy20 that Support Recovery and Growth for Eye Care Practices
-
PM360 Magazine Announces Winners Of 2020 Trailblazer Awards
-
Graybug Vision Inc. (GRAY) Adds Christina Ackermann, Eric Bjerkholt and Julie Eastland to Board
-
Graybug Appoints Three New Members to its Board of Directors
-
Graybug Appoints Three New Members to its Board of Directors
-
Aleafia Health Announces Appointment of Pharmaceutical Executive Tricia Symmes as Chief Commercial Officer
-
Alcon and Actress Katherine McNamara Encourage Consumers to See What Happens with PRECISION1® Contact Lenses
-
Alcon Reports Second Quarter 2020 Results
-
Alcon Reports Second Quarter 2020 Results
-
PM360 Announces 2020 Trailblazer Award Finalists
-
Model N Continues to Lead in Life Sciences Market
-
Wishbone Medical Appoints Jeff George to Board of Directors
-
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
-
Oxurion NV appoints Grace Chang, M.D., Ph.D. as Chief Medical Officer
-
Oculis Announces Successful End-of-Phase 2 Meeting with the FDA for OCS-01 in Two Ophthalmology Indications
-
Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eye
-
Alcon Survey Shows More Screen Time Causing Consumer Concern About Eye Health, Increasing Symptoms of Dry Eye
-
Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales.
-
Alcon (ALC) Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
-
Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
-
Alcon Announces FDA Approval of the OTC Switch of Pataday Once Daily Relief Extra Strength
-
VisionCare, Inc. Names Thomas Ruggia as New Chief Executive Officer
-
Novartis, former unit to pay $346 million to resolve U.S. bribery charges
-
Novartis Resolves Legacy FCPA Investigations
-
CENTOGENE Announces Changes in Senior Management Team
-
CENTOGENE Announces Changes in Senior Management Team
-
Alcon Reports First Quarter 2020 Results
-
Alcon Reports First Quarter 2020 Results
-
BVI Names David Murray as Chief Financial Officer
-
Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19
-
Tango Therapeutics Raises $60 Million Series B Financing and Strengthens Executive Team
-
Alcon Provides Update on COVID-19
-
Alcon Provides Update on COVID-19
-
Oxurion NV Business Update – FY 2019
-
Oxurion NV Business Update – FY 2019
-
Aldeyra Therapeutics (ALDX) Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease
-
Aldeyra Announces Strategic Prioritization of Late-Stage Clinical Pipeline in Ocular Disease
-
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement
-
Nicox to Receive €15 Million and Half of the Cost of the Second NCX 470 Phase 3 Clinical Trial from Ocumension Therapeutics under Amended Agreement
-
Alcon Showcases Contact Lens, Eye Allergy and Dry Eye Innovations as Title Sponsor of #SECO2020
-
Alcon Showcases Contact Lens, Eye Allergy and Dry Eye Innovations as Title Sponsor of #SECO2020
-
Alcon Reports Full Year 2019 Results
-
Alcon Reports Full Year 2019 Results
-
Edward Jones Reiterates Buy Rating on Novartis (NVS), Favors Attractive Pipeline
-
Eyevance Pharmaceuticals Appoints Julie Speed as Chief Commercial Officer
-
Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
-
Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
-
Vivendi: Strong Earnings Growth In 2019
-
Publicis Groupe: 2019 Annual Results

